ASCO GU 2017: Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). - Session Highlights

Orlando, Florida USA ( At this years genitourinary cancers symposium in Florida, Dr. Feifer presented data which states that incorporating Abiraterone into clinical practice of Urologists is a realistic and feasible process. The Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC) is a non-Interventional observational study phase IV clinical trial (NCT02364531). The purpose of the study is to assess the urologists experience with incorporation of abiraterone acetate in their practice. The study surveryed a group consisting primarily of urologists of which 2/3 were community practice based and 1/3 were academic. 

Based on survey results, the ease of use and success in integration of abiraterone into a urology practice was stated to be easy by half of the participants. Others said it was easy once they overcame few barriers (46.7%). 3.3% said it was a challening process due to certain identified barriers. The barrieres identified were time involvement and resource issues such as nursing support and lack of appropriate infrastructure. After participation in the COSMIC trial, 90% of the active sites indicated that treating with abiraterone will be part of their practice after the trial. This report indicates that integration of Abiraterone in urology practices is considered feasible for most urologists. There is interest in participating in future trials of this nature among urologists and such studies may help community and acedmic urologist overcome initial barriers. This supports the concept active participation in clinical trials improves ones practice patterns. Clinical trial information: NCT02364531

Author: Andrew Feifer

Written By: Michael J Metcalfe, MD, Fellow of Urologic Oncology Urology, MD Anderson Cancer Center, Houston TX

Ashish M. Kamat, MD, MBBS, FACS, President, International Bladder Cancer Network Chair, Society of Immunotherapy for Cancer (SITC), BCTF, Director of Urologic Oncology Fellowship, Professor of Urology, Attending Surgeon, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston TX

at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA